“味动力”不动了！均瑶健康陷两年净利润亏损，控股润盈生物业绩承诺“打水漂”

Core Viewpoint - Hubei Junyao Health Beverage Co., Ltd. (stock code: 605388.SH) forecasts a net loss of between 216 million yuan and 144 million yuan for the year 2025, indicating a significant decline in profitability compared to the previous year [2][3]. Financial Performance - The company's net profit attributable to shareholders is expected to decrease by 115 million yuan to 187 million yuan, representing a year-on-year decline of 395.14% to 642.71% from a loss of 29.12 million yuan in the same period last year [3]. - The forecasted net profit, excluding non-recurring gains and losses, is projected to be between 233 million yuan and 155 million yuan, a decrease of 97.05 million yuan to 175 million yuan, equating to a year-on-year decline of 167.33% to 301.00% from a loss of 57.99 million yuan last year [3]. Market Environment - The performance decline is attributed to a challenging market environment, with a reduction in market share for dairy beverages and weak downstream customer demand, particularly affecting the traditional room-temperature yogurt business [3][4]. - The company is facing dual challenges: stagnation in its core product "Weidongli" and disproportionate returns from new business investments [8]. Product Performance - "Weidongli," a flagship yogurt product, has seen a continuous decline in net profit over the years, with a drop in revenue from 770 million yuan in 2020 to 580 million yuan in 2023 [10]. - Sales volume for yogurt products has also decreased significantly, with declines of 28.37%, 2.72%, 16.11%, and 10.99% from 2020 to 2023 [10]. Strategic Changes - The company is attempting to optimize its revenue structure by expanding e-commerce, new retail channels, and chain KA channels, which has led to increased upfront sales and marketing expenses [3]. - Junyao Health has initiated a "second entrepreneurship" focusing on the probiotic sector, but the financial contribution from this segment remains limited [13][14]. R&D and Challenges - Increased R&D investment has also contributed to profit erosion, with the company facing scrutiny over the effectiveness of its self-developed strains [15]. - The subsidiary Junyao Runying has not met its profitability targets, with a net profit of only 3.91 million yuan, far below the set annual goal of 180 million yuan [14][15].